Ísrael - enska - Ministry of Health

glaxo smith kline (israel) ltd - paroxetine as hydrochloride - coated tablets - paroxetine as hydrochloride 20 mg - paroxetine - treatment of (in adults):­ major depressive disorder ­ obsessive compulsive disorder (ocd)­ panic disorder with and without agoraphobia­ social anxiety disorders/social phobia­ generalised anxiety disorder­ post-traumatic stress disorder

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; lactose; hyprolose; hypromellose; macrogol 8000; titanium dioxide - treatment of major depression and prevention of relapse of depressive symptoms. treatment of obsessive compulsive disorder (ocd) and prevention of relapse of ocd. treatment of panic disorder and prevention of relapse of panic disorder. treatment of social anxiety disorder / social phobia. treatment of generalised anxiety disorder. treatment of post-traumatic stress disorder.

Ísrael - enska - Ministry of Health

devries & co. ltd - betamethasone - tablets - betamethasone 0.5 mg - betamethasone - betamethasone - diseases responsive to oral glucocorticosteroid therapy.

Ísrael - enska - Ministry of Health

reckitt benckiser (near east) ltd - ibuprofen - tablets - ibuprofen 200 mg - ibuprofen - ibuprofen - relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.

Ísrael - enska - Ministry of Health

novartis israel ltd - methylphenidate hydrochloride - tablets - methylphenidate hydrochloride 10 mg - methylphenidate - methylphenidate - attention deficit hyperactivity disorder (adhd). narcolepsy.

Ísrael - enska - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - tablets - montelukast as sodium 10 mg - montelukast - montelukast - singulair 10 mg is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms of the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.

Ísrael - enska - Ministry of Health

novartis israel ltd - methylphenidate hydrochloride - tablets - methylphenidate hydrochloride 20 mg - methylphenidate - attention deficit hyperactivity disorders . narcolepsy.

Ísrael - enska - Ministry of Health

merck sharp & dohme israel ltd - rizatriptan as benzoate - tablets - rizatriptan as benzoate 5 mg - rizatriptan - rizatriptan - rizalt is indicated for the acute treatment of migraine attacks with or without aura in adults

Ísrael - enska - Ministry of Health

organon pharma israel ltd., israel - rizatriptan as benzoate - tablets - rizatriptan as benzoate 10 mg - rizatriptan - rizatriptan - rizalt is indicated for the acute treatment of migraine attacks with or without aura in adults.

Ísrael - enska - Ministry of Health

taro international ltd, israel - esomeprazole - tablets - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophgeal reflux disease (gerd)in combination with antibiotics in treatment of duodenal ulcer caused by helicobactor pylori